Jazz Pharmaceuticals prices upsized USD 1.1 billion exchangeable senior notes offering due 2032

Jazz Pharmaceuticals priced an upsized private offering of USD 1.1 billion 1.875% exchangeable senior notes due 2032.

• The deal was increased from the previously announced USD 1 billion.
• Initial purchasers hold an option for up to USD 150 million more.
• Net proceeds are estimated at about USD 1.08 billion, or about USD 1.23 billion if the option is exercised in full.
• The offering is expected to close Aug. 31, 2026, and proceeds are earmarked for general corporate purposes.
• Concurrent with pricing, the company repurchased about USD 225 million of ordinary shares at USD 249.29 per share.